
PB 45 of 2026
National Health (June 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026
I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following determination.
Dated 29 April 2026
REBECCA RICHARDSON
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
(1) This instrument is the National Health (June 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026.
(2) This instrument may also be cited as PB 45 of 2026.
This instrument commences on 1 June 2026.
This instrument is made under sections 99ACB and 99ACD of the National Health Act 1953.
Note: A number of expressions used in this instrument are defined in Part VII the Act.
In this instrument:
Act means the National Health Act 1953.
Reduction day refers to 1 June 2026.
5 Brands of pharmaceutical item (combination items) not subject to a price reduction
6 Brands of pharmaceutical item (not combination items) not subject to a price reduction
Part 1
Column 1 | Column 2 | |||
Item | Brand of pharmaceutical item | |||
| Drug | Form | Manner of administration | Brand |
1 | Drospirenone with ethinylestradiol | Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol and 7 inert tablets | Oral | Mila |
Part 1
Column 1 | Column 2 | |||
Item | Brand of pharmaceutical item | |||
| Drug | Form | Manner of administration | Brand |
1 | Febuxostat | Tablet 80 mg | Oral | Febexic |